Robert Driscoll
Stock Analyst at Wedbush
(1.84)
# 3,160
Out of 4,944 analysts
157
Total ratings
28.57%
Success rate
-7.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Downgrades: Neutral | $19 → $4 | $5.25 | -23.81% | 6 | Jul 22, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $27 | $13.07 | +106.58% | 1 | Jul 14, 2025 | |
| KURA Kura Oncology | Reiterates: Outperform | $36 | $6.20 | +480.65% | 10 | Jun 20, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Neutral | $4 | $1.41 | +183.69% | 11 | May 15, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Outperform | $8 → $6 | $1.19 | +404.20% | 3 | May 9, 2025 | |
| RVMD Revolution Medicines | Reiterates: Outperform | $67 | $35.26 | +90.02% | 5 | Apr 28, 2025 | |
| GLUE Monte Rosa Therapeutics | Maintains: Outperform | $15 → $17 | $4.45 | +282.02% | 4 | Mar 21, 2025 | |
| ARVN Arvinas | Downgrades: Neutral | $57 → $12 | $6.80 | +76.60% | 9 | Mar 12, 2025 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Outperform | $32 | $6.14 | +421.17% | 6 | Feb 26, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $52 | $23.62 | +120.20% | 9 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $10.60 | +164.15% | 8 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $2.54 | +529.92% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $9.67 | +210.24% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $22 | $1.30 | +1,592.31% | 10 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $51 | $8.96 | +469.20% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.64 | +682.47% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $7.29 | +394.17% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $1.70 | +547.06% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $4.87 | +166.94% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $6.76 | +92.31% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $24.27 | +204.90% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $3.17 | +152.37% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.35 | +418.52% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $1.86 | +330.11% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $3.40 | +17.82% | 4 | May 19, 2020 |
Replimune Group
Jul 22, 2025
Downgrades: Neutral
Price Target: $19 → $4
Current: $5.25
Upside: -23.81%
Crescent Biopharma
Jul 14, 2025
Initiates: Outperform
Price Target: $27
Current: $13.07
Upside: +106.58%
Kura Oncology
Jun 20, 2025
Reiterates: Outperform
Price Target: $36
Current: $6.20
Upside: +480.65%
Zentalis Pharmaceuticals
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $1.41
Upside: +183.69%
Werewolf Therapeutics
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $1.19
Upside: +404.20%
Revolution Medicines
Apr 28, 2025
Reiterates: Outperform
Price Target: $67
Current: $35.26
Upside: +90.02%
Monte Rosa Therapeutics
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $4.45
Upside: +282.02%
Arvinas
Mar 12, 2025
Downgrades: Neutral
Price Target: $57 → $12
Current: $6.80
Upside: +76.60%
Day One Biopharmaceuticals
Feb 26, 2025
Reiterates: Outperform
Price Target: $32
Current: $6.14
Upside: +421.17%
IDEAYA Biosciences
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $23.62
Upside: +120.20%
Oct 25, 2024
Reiterates: Outperform
Price Target: $28
Current: $10.60
Upside: +164.15%
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $2.54
Upside: +529.92%
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $9.67
Upside: +210.24%
Oct 1, 2024
Maintains: Outperform
Price Target: $25 → $22
Current: $1.30
Upside: +1,592.31%
Sep 20, 2024
Maintains: Outperform
Price Target: $85 → $51
Current: $8.96
Upside: +469.20%
Sep 20, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.64
Upside: +682.47%
Sep 18, 2024
Reiterates: Outperform
Price Target: $36
Current: $7.29
Upside: +394.17%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $1.70
Upside: +547.06%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $4.87
Upside: +166.94%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $6.76
Upside: +92.31%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $24.27
Upside: +204.90%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $3.17
Upside: +152.37%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.35
Upside: +418.52%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $1.86
Upside: +330.11%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $3.40
Upside: +17.82%